From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Structural diagram of miglitol
Clinical data
Trade names Glyset
AHFS/Drugs.com Monograph
MedlinePlus a601079
License data
  • AU: B3
  • US: B (No risk in non-human studies)
Routes of
By mouth (tablets)
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability Dose-dependent
Protein binding Negligible (<4.0%)
Metabolism Nil
Elimination half-life 2 hours
Excretion Renal (95%)
CAS Number
PubChem CID
ECHA InfoCard 100.069.670 Edit this at Wikidata
Chemical and physical data
Formula C8H17NO5
Molar mass 207.224 g/mol
3D model (JSmol)
Density 1.458 g/cm3
Melting point 114 °C (237 °F)

Miglitol is an oral anti-diabetic drug that acts by inhibiting the ability of the patient to break down complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body.[1]

Miglitol, and other structurally-related iminosugars, inhibit glycoside hydrolase enzymes called alpha-glucosidases. Since miglitol works by preventing digestion of carbohydrates, it lowers the degree of postprandial hyperglycemia. It must be taken at the start of main meals to have maximal effect.[2] Its effect will depend on the amount of non-monosaccharide carbohydrates in a person's diet.

In contrast to acarbose (another alpha-glucosidase inhibitor), miglitol is systemically absorbed; however, it is not metabolized and is excreted by the kidneys.

See also[edit]


  1. ^ "Migliotl: MedlinePlus Drug Information". MedlinePlus. National Institutes of Health. 1 September 2010. Retrieved 13 April 2013. 
  2. ^ "Glyset (miglitol) tablets label - Accessdata FDA" (PDF). Drugs@FDA. U.S. Food and Drug Administration. August 2012. Retrieved 13 April 2013.